In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Cellectis SA

From Auto To Allo: Poseida Tries To Pick The Winning CAR-T Team

The company is winding down its autologous myeloma CAR-T program as competition in that market heats up and interest in off-the-shelf CAR-Ts grows.

Cancer Business Strategies

KRAS Inhibitors Show Promise But Long Road Ahead, Say Experts

Harvard Medical School’s Dr. Bruce Chabner, Bayer Pharma’s global head of research and Roivant Sciences founder, among others, share their views on the challenges and path ahead for KRAS inhibitors and other oncology modalities including CAR-T therapy.

Cancer Research & Development

Deal Watch: ICON, PRA Health Form Massive CRO In $12bn Merger

Plus deals involving Sanofi/SIRION, Merck KGAA/Day One, Beijing Tide/Graviton, Vaccinex/Surface Oncology, Athena/Tris, Biomunex/Onward, Cellectis/Cytovia

Deals M & A

Keytruda Combination Gives Celyad’s Off-The-Shelf CAR-T A Shot In The Arm

Celyad has been in the CAR-T field for many years, but hopes that a new focus on allogeneic platforms and new targets will put it ahead of competitors. 

Companies Cancer
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Drug Discovery Tools
      • Genomics-Proteomics
      • Molecular Diversity
        • Natural Products
  • Other Names / Subsidiaries
    • Calyxt
UsernamePublicRestriction

Register